Vaso Stock Price, News & Analysis (OTCMKTS:VASO) $0.23 -0.01 (-4.19%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$0.23▼$0.2350-Day Range$0.23▼$0.3552-Week Range$0.16▼$0.37Volume38,980 shsAverage Volume102,041 shsMarket Capitalization$42.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About Vaso Stock (OTCMKTS:VASO)Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.Read More VASO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VASO Stock News HeadlinesDecember 1, 2023 | foxnews.com'Z' author Vassilis Vassilikos dies at 89 in AthensNovember 30, 2023 | abcnews.go.comGreek author Vassilis Vassilikos, whose political novel inspired award-winning film 'Z,' dies at 89December 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 27, 2023 | chron.comGranada anuncia que el uruguayo Alexander Medina será su nuevo técnicoNovember 17, 2023 | msn.comAlbania’s Resistance Movement Achieved a Unique Victory in the Struggle Against NazismNovember 16, 2023 | businesswire.comVertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the ...November 16, 2023 | msn.comBiggest stock movers today: Cisco Systems, Palo Alto Networks and moreNovember 14, 2023 | finance.yahoo.comVaso Corporation Announces Financial Results for Third Quarter 2023December 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 4, 2023 | markets.businessinsider.comGeulah Livshits Rates Editas Medicine as ‘Buy’: Promising Clinical Trials and Stable Financial OutlookNovember 4, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Boost Editas Medicine’s Buy Rating: An AnalysisNovember 2, 2023 | forbes.comTwo Sickle Cell Disease Gene Therapies May Soon Be Approved By FDANovember 1, 2023 | morningstar.comVaso Corporation VASONovember 1, 2023 | msn.comBiggest stock movers today: AMD, WeWork, Paycom Software, CRISPR Therapeutics and moreNovember 1, 2023 | msn.comBiggest stock movers today: Paycom Software, CRISPR Therapeutics and moreOctober 31, 2023 | msn.comCRISPR, Vertex gene editing therapy gets warm response from FDA panelOctober 14, 2023 | msn.comShopper Blog: Madi Grace Boutique in Powell features a special 'Confetti Closet'October 11, 2023 | news.yahoo.comShopper Blog: James Harrison is racing to show 'One Dad Can' help those with sickle cell diseaseOctober 6, 2023 | msn.comChelsea hold Andrey Santos talks with Nottingham Forest over loanee’s lack of gametimeOctober 5, 2023 | bizjournals.comFive Oregon wines make a global 'Best Buy' listOctober 4, 2023 | msn.comTaste Of Joliet's Headliner Cost $300,000, Record TurnoutSeptember 28, 2023 | msn.comBest of the RGV: EloteSeptember 28, 2023 | reuters.comGeorgia overhaul backline as they look to fire against FijiSeptember 26, 2023 | finance.yahoo.comOTC Markets Group Welcomes Vaso Corporation to OTCQXSeptember 25, 2023 | finance.yahoo.comVaso Corporation Announces Upgrade to OTCQX Best Market from OTCQB Venture MarketSeptember 25, 2023 | msn.com'It Feels Like A Thousand Needles Are Being Poked Into You At Once': The Physical And Mental Toll Of Sickle Cell DiseaseSeptember 24, 2023 | msn.comHow To Taste The Flavor Differences Between Mezcal And TequilaSee More Headlines Receive VASO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaso and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:VASO CUSIPN/A CIK839087 Webwww.vasocorporation.com Phone516-997-4600Fax516-997-2299Employees272Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$11.87 million Net Margins14.63% Pretax Margin8.89% Return on Equity49.90% Return on Assets16.77% Debt Debt-to-Equity RatioN/A Current Ratio1.43 Quick Ratio1.38 Sales & Book Value Annual Sales$80.02 million Price / Sales0.53 Cash Flow$0.08 per share Price / Cash Flow3.05 Book Value$0.14 per share Price / Book1.63Miscellaneous Outstanding Shares185,627,000Free Float102,912,000Market Cap$42.46 million OptionableNot Optionable Beta2.44 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Jun Ma Ph.D. (Age 60)President, CEO & Director Comp: $805.32kMr. Jonathan P. Newton (Age 62)Co-CFO, VP of Finance & Treasurer Comp: $346.42kMr. Michael J. Beecher CPA (Age 78)CPA, Co-CFO & Secretary Comp: $125.36kMr. Peter C. Castle (Age 55)Chief Operating Officer Comp: $383.37kMs. Jane Moen (Age 43)President of VasoHealthcare & Director Comp: $549.89kMr. Shen QiumingPresident of Biox Instruments Co LtdMr. Randy Hill (Age 76)Consultant Comp: $105kDr. Derek Enlander M.D. (Age 77)Advisor Comp: $12kMore ExecutivesKey CompetitorsMovanoNASDAQ:MOVEVivani MedicalNASDAQ:VANIPrecision OpticsNASDAQ:POCIelectroCoreNASDAQ:ECORPrecision OpticsOTCMKTS:PEYEView All Competitors VASO Stock Analysis - Frequently Asked Questions How have VASO shares performed in 2023? Vaso's stock was trading at $0.1650 at the beginning of 2023. Since then, VASO shares have increased by 38.6% and is now trading at $0.2288. View the best growth stocks for 2023 here. Are investors shorting Vaso? Vaso saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,800 shares, an increase of 528.6% from the October 31st total of 1,400 shares. Based on an average daily volume of 262,900 shares, the short-interest ratio is presently 0.0 days. View Vaso's Short Interest. How were Vaso's earnings last quarter? Vaso Co. (OTCMKTS:VASO) issued its quarterly earnings data on Tuesday, November, 14th. The company reported $0.01 earnings per share for the quarter. The firm earned $19.45 million during the quarter. Vaso had a net margin of 14.63% and a trailing twelve-month return on equity of 49.90%. What other stocks do shareholders of Vaso own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaso investors own include Andeavor (ANDV), Aramark (ARMK), GoPro (GPRO), Kimco Realty (KIM), New York Community Bancorp (NYCB), PB Bancorp (PBBI), R. R. Donnelley & Sons (RRD), Tyson Foods (TSN) and VMware (VMW). How do I buy shares of Vaso? Shares of VASO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:VASO) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaso Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.